// App-Quantinova.ai

745 : IMP-MEL: a phase 1 first-in-human dose-finding study of a novel invariant natural killer T-cell agonist (iNKT) IMM60 in advanced melanoma and non-small-cell lung cancer (NSCLC)

Researchers

Presenter

  • Nicholas Coupe

Principal Investigators

  • Ian Walters

  • Justin Fairchild

  • Matthew Parkes

  • David Thompson

  • Robert Kramer

  • Uzi Gileadi

  • Mark Middleton

Medical Centers

  • Oxford University Hospital, Oxford,

  • Portage BioTech, Westport, CT, USA

  • University of Oxford, Oxford, Germany

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • IFN-lambda

Outcome

  • N/A

Study Design

  • Pharmacodynamics

  • Open Label

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved